Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer

BACKGROUND: Satraplatin is an oral platinum compound that has demonstrated efficacy and tolerability in prostate cancer. Preclinical synergy between bevacizumab and platinum has been noted. METHODS: Docetaxel-pretreated metastatic castrate-resistant prostate cancer patients with disease progression...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Vaishampayan, Ulka N., Fontana, Joseph, Heilbrun, Lance K., Smith, Daryn, Heath, Elisabeth, Dickow, Brenda, Figg, William D.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3872261/
https://ncbi.nlm.nih.gov/pubmed/23433892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2012.11.017
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki